Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy

NCT02014909 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02014909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02014909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
June 5, 2017
Enrollment
64 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer